CYP7A1 and type 2 diabetes mellitus: The animal studies showed that, compared with the T2DM group, the group treated with COS showed inhibited transcriptional regulation of HMGCR and reduced SMYD3 expression, while treatment with COS upregulated the cholesterol-degrading enzymes CYP7A1 and incretin GLP-1 (Figure 4).